Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

E.D. Capoluongo, B. Pellegrino, L. Arenare, D. Califano, G. Scambia, L. Beltrame, V. Serra, G.L. Scaglione, A. Spina, S.C. Cecere, R. De Cecio, N. Normanno, N. Colombo, D. Lorusso, D. Russo, C. Nardelli, M. D'Incalci, A. Llop-Guevara, C. Pisano, G. BaldassarreD. Mezzanzanica, G. Artioli, M. Setaro, G. Tasca, C. Roma, N. Campanini, S. Cinieri, A. Sergi, A. Musolino, F. Perrone, P. Chiodini, S. Marchini, S. Pignata

Research output: Contribution to journalArticlepeer-review


Background: The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP ribose polymerase inhibitors (PARPi). MyChoice CDx (Myriad) is the most used HRD test in ovarian cancer (OC). However, some limitations of commercial tests exist, because of the high rate of inconclusive results, costs, and the impossibility of evaluating functional resistance mechanisms. Patients and methods: Two academic genomic tests and a functional assay, the RAD51 foci, were evaluated to detect HRD. One hundred patients with high-grade OC enrolled in the MITO16A/MaNGO-OV2 trial and treated with first-line therapy with carboplatin, paclitaxel, and bevacizumab were analyzed. Results: The failure rate of the two genomic assays was 2%. The sensitivity in detecting HRD when compared with Myriad was 98.1% and 90.6%, respectively. The agreement rate with Myriad was 0.92 and 0.87, with a Cohen's κ coefficient corresponding to 0.84 and 0.74, respectively. For the RAD51 foci assay, the failure rate was 30%. When the test was successful, discordant results for deficient and proficient tumors were observed, and additional HRD patients were identified compared to Myriad; sensitivity was 82.9%, agreement rate was 0.65, and Cohen's κ coefficient was 0.18. The HRD detected by genomic assays and residual tumor at primary surgery and stage was correlated with progression-free survival at multivariate analysis. Conclusions: Results suggest the feasibility of academic tests for assessing HRD status that show robust concordance with Myriad and correlation with clinical outcome. The contribution of the functional information related to the RAD51 foci test to the genomic data needs further investigation.

Original languageEnglish
JournalESMO Open
Issue number5
Publication statusPublished - 2022


Dive into the research topics of 'Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial'. Together they form a unique fingerprint.

Cite this